Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements Pharmaceutical Investing
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients Pharmaceutical Investing
Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer Pharmaceutical Investing
MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy Pharmaceutical Investing
Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe Pharmaceutical Investing
Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial Pharmaceutical Investing
Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis Pharmaceutical Investing
Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression Biotech Investing
